Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 32 Issue 1
. 
Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2014  >  32(1): 61-64

WENG Lizhu. Comparison of the effect of moxifloxacin and levofloxacin on treatment of multi-drug resistant pulmonary tuberculosis[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(1): 61-64. doi: 10.3969/j.issn.1006-0111.2014.01.017
Citation: WENG Lizhu. Comparison of the effect of moxifloxacin and levofloxacin on treatment of multi-drug resistant pulmonary tuberculosis[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(1): 61-64. doi: 10.3969/j.issn.1006-0111.2014.01.017
shu

Comparison of the effect of moxifloxacin and levofloxacin on treatment of multi-drug resistant pulmonary tuberculosis

doi: 10.3969/j.issn.1006-0111.2014.01.017

  • Department of Infectious Diseases, Yuhuan County People's Hospital of Zhejiang Province, Yuhuan 317600, China

  • Received Date: 2013-04-23
  • Rev Recd Date: 2013-09-06
  • Objective To compare the clinical effect of moxifloxacin and levofloxacin on treatment of multi-drug resistant pulmonary tuberculosis(TB). Methods From Jan 2011 to Dec 2012, 108 patients who were proved to be multi-drug resistant to tuberculosis in Yuhuan County People's Hospital of Zhejiang Province were included in the study. The patients were divided into moxifloxacin treatment group or levofloxacin treatment group by computer-generated random number and randomly allocated method. The treatment regimens were as follows:in moxifloxacin treatment group, the patients were given moxifloxacin, pasiniazid, pyrazinamide, protionamide, rifapentine, sodium aminosalicylate, and amikacin for 3 months, followed by 6 months treatment of moxifloxacin, pyrazinamide, protionamide, pasiniazid and rifapentine, then moxifloxacin, rifapentine, pyrazinamide, andpasiniazid for 9 months. In levofloxacin treatment group, moxifloxacin was replaced by levofloxacin, and other combinations were same as moxifloxacin group. The treatment time was 18 months in 2 groups. Results At the end of the study, 41 of 53 patients finished the treatment in moxifloxacin-group and 44 of 55 patients finished the treatment in levofloxacin-group. Mortalities were 9.4%(5/53)in moxifloxacin-group and 9.1%(5/55) in levofloxacin-group, respectively. The sputum negative rate was 87.8%(36/41) and 84.1%(37/44) in each group, respectively. The effective rate of chest X ray was 92.7%(38/41) in moxifloxacin group and 93.2%(41/44) in levofloxacin group, and the cavity closure rate were 39%(16/41)and 43.2%(19/44). The rate of serious adverse drug reactions was 13.2%(7/53) and 10.9%(6/55), respectively. There was no significant difference between 2 groups. Conclusion Moxifloxacin combined with other drugs to treat multi-drug-resistant TB had no significant advantages compared to levofloxacin combined with the same drugs.
  • [1] 朱莉贞,傅 瑜,初乃惠,等.利福类联合多种药物长疗程方案治疗耐多药肺结核[J].中华结核和呼吸杂志,2006,29(8):320-323.
    [2] Centers for Disease Control and Prevention (CDC).Emergence of mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide,2000-2004[J].MMWR Morb Mortal Wkly ReP,2006,55(11):301-305.
    [3] Centers for Disease Control and Prevention (CDC).Plan to combat extensively drug resistant tuberculosis:recommendations of the Federal Tuberculosis Task Force[J].MMWR Recomm ReP,2009,58(RR-3):1-43.
    [4] Musser JM. Antimicrobial agent resistantce in mycrobacteria:molecular genetic insights[J]. Clin Microbiol Rev,1995,8(2):495-514.
    [5] 何国钧.多重耐药性结核病及其治疗[J].中国防痛杂志,1997,19(增刊):30-32.
    [6] 曾正国.现代实用结核病学[M].北京:科学技术文献出版社,2003:228-235.
    [7] Fattorini L,Tan D,lona E,et al. Activity of moxifloxacin alone and in combination with other antimicrobial agents multidrug-resistant mycrobacterium tuberculosis infection in BALB/c mice[J]. Antimicrob Agents Chemother,2003,47(1):360-362.
    [8] Nuermberger EL,Yoshimatsu T. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis[J]. Am J Respir Crit Care Med,2004,170(10):1131-1134.
    [9] Johnson JL,Hadad DJ.Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis[J]. Int J Tuberc Lung Dis,2006,10(6):605-612.
    [10] 梁丽丽,刘 欣.联合应用莫西沙星或左氧氟沙星治疗耐多药肺结核疗效研究[J].中国全科医学,2011,13:1451-1453.
  • 加载中
通讯作者: 陈斌, [email protected]
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(2984) PDF downloads(101) Cited by()

Related
Proportional views

Comparison of the effect of moxifloxacin and levofloxacin on treatment of multi-drug resistant pulmonary tuberculosis

doi: 10.3969/j.issn.1006-0111.2014.01.017
  • Department of Infectious Diseases, Yuhuan County People's Hospital of Zhejiang Province, Yuhuan 317600, China
  • Received Date: 2013-04-23
  • Rev Recd Date: 2013-09-06

Abstract: Objective To compare the clinical effect of moxifloxacin and levofloxacin on treatment of multi-drug resistant pulmonary tuberculosis(TB). Methods From Jan 2011 to Dec 2012, 108 patients who were proved to be multi-drug resistant to tuberculosis in Yuhuan County People's Hospital of Zhejiang Province were included in the study. The patients were divided into moxifloxacin treatment group or levofloxacin treatment group by computer-generated random number and randomly allocated method. The treatment regimens were as follows:in moxifloxacin treatment group, the patients were given moxifloxacin, pasiniazid, pyrazinamide, protionamide, rifapentine, sodium aminosalicylate, and amikacin for 3 months, followed by 6 months treatment of moxifloxacin, pyrazinamide, protionamide, pasiniazid and rifapentine, then moxifloxacin, rifapentine, pyrazinamide, andpasiniazid for 9 months. In levofloxacin treatment group, moxifloxacin was replaced by levofloxacin, and other combinations were same as moxifloxacin group. The treatment time was 18 months in 2 groups. Results At the end of the study, 41 of 53 patients finished the treatment in moxifloxacin-group and 44 of 55 patients finished the treatment in levofloxacin-group. Mortalities were 9.4%(5/53)in moxifloxacin-group and 9.1%(5/55) in levofloxacin-group, respectively. The sputum negative rate was 87.8%(36/41) and 84.1%(37/44) in each group, respectively. The effective rate of chest X ray was 92.7%(38/41) in moxifloxacin group and 93.2%(41/44) in levofloxacin group, and the cavity closure rate were 39%(16/41)and 43.2%(19/44). The rate of serious adverse drug reactions was 13.2%(7/53) and 10.9%(6/55), respectively. There was no significant difference between 2 groups. Conclusion Moxifloxacin combined with other drugs to treat multi-drug-resistant TB had no significant advantages compared to levofloxacin combined with the same drugs.

WENG Lizhu. Comparison of the effect of moxifloxacin and levofloxacin on treatment of multi-drug resistant pulmonary tuberculosis[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(1): 61-64. doi: 10.3969/j.issn.1006-0111.2014.01.017
Citation: WENG Lizhu. Comparison of the effect of moxifloxacin and levofloxacin on treatment of multi-drug resistant pulmonary tuberculosis[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(1): 61-64. doi: 10.3969/j.issn.1006-0111.2014.01.017
shu

    HTML

Reference (10)

Catalog

    版权所有：《药学实践与服务》编辑委员会

    Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

    Tel: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return